{"id":"NCT00868296","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","briefTitle":"Open Label Safety Study of Enteric-Coated Spheroid Suspension in Infants Aged Less Than 12 Months With Presumed Gastroesophageal Reflux Disease (GERD)","officialTitle":"A Muliticenter, Open Label Safety Study of 2 Doses of Pantoprazole Sodium Enteric-Coated Spheroid Suspension in Infants Aged Less Than 12 Months With Presumed GERD","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-03","primaryCompletion":"2008-03","completion":"2008-03","firstPosted":"2009-03-24","resultsPosted":"2010-01-07","lastUpdate":"2010-05-04"},"enrollment":58,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Gastroesophageal Reflux"],"interventions":[{"type":"DRUG","name":"pantoprazole","otherNames":[]}],"arms":[{"label":"Low dose","type":"ACTIVE_COMPARATOR"},{"label":"High dose","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to provide additional information on safety and tolerability after multiple does of pantoprazole. Only patients who successfully completed the 3001B3-331 study (NCT00362609) or 3001B3-333 study (NCT00259012) are eligible to participate in this study.","primaryOutcome":{"measure":"Number of Patients With Laboratory Test Values of Potential Clinical Importance During Treatment Period","timeFrame":"6 weeks","effectByArm":[{"arm":"Low Dose Pantoprazole","deltaMin":0,"sd":null},{"arm":"High Dose Pantoprazole","deltaMin":3,"sd":null}],"pValues":[]},"eligibility":{"minAge":"1 Day","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":1},"locations":{"siteCount":71,"countries":["United States","Australia","Belgium","Canada","France","Germany","Italy","Netherlands","Poland","South Africa","Switzerland"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1},"commonTop":["Rhinitis","Otitis media","Fever","Tooth disorder","Cough increased"]}}